StockData

BioCardia vs Alaunos Therapeutics

BCDA and TCRT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BCDA and TCRT compare

BioCardia is the larger company, worth 3.0 times as much as Alaunos Therapeutics ($12.6M against $4.1M).

BioCardia scores higher on the StockData Score (5 against 4 for Alaunos Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBCDATCRT
Size and price
Market cap$12.6M$4.1M
Share price$0.831$1.63
Change, 1 year−36.1%−45.5%
Change, 5 years−97.5%−99.2%
Beta (5Y)1.00−0.42
Employees211
StockData Score
Total score5 (better)4
Valuation score00
Growth score00
Performance score00
Health score5 (better)4
Dividend score00
Valuation
P/S–1380×
P/B15.1×6.4× (better)
FCF yield−60.6%–
Growth
Revenue growth (TTM)–−50.0%
Profitability
Operating margin–−135267%
Net margin–−133667%
Return on equity−443%−186% (better)
Return on invested capital–−489%
Financial health
Debt / equity0.000.00
Current ratio1.11 (better)0.77
Altman Z-score−84.18 (better)−861.79
Piotroski F-score33
Dividends and buybacks
Buyback yield−42.2%–
Shareholder yield−42.2%0.00% (better)
Ownership
Held by institutions8.8%3.6%
Held by insiders11.7%69.8%
Insider net buying, 12 months$170K–
Short interest, % of float5.5%24.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.